NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Despite any news yesterday, shares of Altimmune were soaring and closed up roughly 285%. It was in early September that the company announced positive mid-stage data on its intranasal egg-free flu vaccine candidate
RDI Initiates Coverage on:
Molecular Templates, Inc.
https://rdinvesting.com/news/?ticker=MTEM
Altimmune, Inc.
https://rdinvesting.com/news/?ticker=ALT
Molecular Templates, Inc. shares closed up 52.44% on a little over 7 million shares traded yesterday. The clinical-stage oncology company was exploding on the news that it had announced an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma. Under terms of the agreement, Takeda will make an upfront payment of $30 million, and Molecular Templates will be eligible to receive up to $632.5 million in milestone payments if the company exercises its co-development option, or up to $337.5 in payments if the option is not exercised. “We have worked closely with Takeda’s scientific team since October 2016 to develop CD38-targeted ETBs with substantial improvements over our own internal program, MT-4019,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive
Access RDI’s Molecular Templates, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MTEM
Altimmune, Inc. was one of the biggest winners on the NASDAQ on Wednesday, closing the day up with 285.48% in gains. It was a couple of weeks ago that the company announced positive mid-stage data on its intranasal egg-free flu vaccine candidate
Access RDI’s Altimmune, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ALT
Our Actionable Research on Molecular Templates, Inc. (NASDAQ: MTEM) and Altimmune, Inc. (NASDAQ: ALT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/512287/Todays-Research-Reports-on-Stocks-to-Watch-Molecular-Templates-and-Altimmune